1. Home
  2. TROO vs CABA Comparison

TROO vs CABA Comparison

Compare TROO & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TROOPS Inc.

TROO

TROOPS Inc.

HOLD

Current Price

$3.39

Market Cap

235.8M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.02

Market Cap

212.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TROO
CABA
Founded
2005
2017
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.8M
212.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
TROO
CABA
Price
$3.39
$3.02
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
644.8K
3.8M
Earning Date
10-17-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,084,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
247.24
N/A
52 Week Low
$0.49
$0.99
52 Week High
$5.28
$3.67

Technical Indicators

Market Signals
Indicator
TROO
CABA
Relative Strength Index (RSI) 51.28 67.87
Support Level $3.61 $2.04
Resistance Level $4.08 $3.34
Average True Range (ATR) 0.58 0.21
MACD -0.15 0.11
Stochastic Oscillator 2.92 75.39

Price Performance

Historical Comparison
TROO
CABA

About TROO TROOPS Inc.

TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: